Aging Global Demographics And Pipelines Will Expand Rare Therapies

Published
15 Apr 25
Updated
15 Aug 25
AnalystHighTarget's Fair Value
US$122.00
52.9% undervalued intrinsic discount
15 Aug
US$57.44
Loading
1Y
-38.1%
7D
1.1%

Author's Valuation

US$122.0

52.9% undervalued intrinsic discount

AnalystHighTarget Fair Value

Shared on07 May 25
Fair value Decreased 4.61%

Shared on30 Apr 25
Fair value Increased 1.23%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25
Fair value Increased 3.55%

AnalystHighTarget has increased future PE multiple from 20.1x to 22.7x.